EuroPCR 2022 | Real World Outcomes on Edge-to-Edge Tricuspid Valve Repair: 30 Day Outcomes of the TriClip bRight

This study was carried out to assess the safety and efficacy of the TriClip (edge-to-edge repair) in patients with severe tricuspid regurgitation with persistent symptoms despite medical treatment and high surgical risk. 

Desenlaces del mundo real sobre la reparación tricuspídea borde a borde: Resultados a 30 días del estudio TriClip bRight

It is a prospective multicenter single arm study including 300 patients of mean age 78±7.6; 7.7% presented prior aortic intervention and 28% prior mitral intervention.  

Primary end point was procedural related success, defined as survival at discharge with successful TriClip implantation. The study looked at patients with diverse tricuspid anatomies (real world population).

At 30 days, there was 91% implantation success rate, with average procedure duration 101 min, 71% of patients improved tricuspid regurgitation (vs 1% of baseline population). The safety profile at 30 days rendered 1% MACE.  

Conclusions

The TriClip showed safety at 30 days seeing as there was 1% MACE, and reduced TR severity. The bRIGHT study is still enrolling (searching n=500) to assess the behavior of this device across diverse tricuspid anatomies. 

Reference: Presented by en Late-breaking clinical trial en EuroPCR 2022 por Dr Phillipp Lurz.

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the editorial board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...